Analysis of Circulating Tumor Markers in the Blood

Monitoring of patients with tumours treated by immune therapy.

Timing of blood sampling:

• inclusion
• after #8 weeks on therapy
• at progression or 6 months from inclusion for patient without progressive disease
• if toxicity grade 3 or 4, or grade 2 until 1 month.

Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).

Timing of blood sampling:

• inclusion
• after 1 cycle of therapy (weeks 3-4)
• up to 2 other samples, timepoints decided by the investigator

Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).

One tumor sampling.

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).

One tumor sampling.

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.

One tumor sampling.

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.

One tumor sampling.

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients treated with palbociclib

Timing of blood sampling:

• Inclusion day (2 samples)
• after #2 weeks of therapy
• after #4 weeks of therapy
• at progression.

Detection of PD-L1 in metastatic breast cancer patients

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Detection of PD-L1 in metastatic lung cancer patients

Timing of blood sampling:

• Inclusion
• up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.

Blood sampling at 4 timepoints.

Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.

Blood sampling at 4 timepoints.

Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.

Blood sampling at 4 timepoints.

Monitoring of patient with a metastatic breast cancer treated by palbociclib.

Timing of blood sampling:

• Inclusion
• after #4 weeks of therapy
• at the first tumoral evaluation (month 3 or 4)
• at progression.

The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.

Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.

Timing of blood sampling:

• Inclusion
• after #3-5 weeks of therapy
• at the first tumoral evaluation (month 2 or 3)
• at progression.

The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).

Timing of blood sampling:

• J1C1
• J2C1
• J1C2
• J1C5 (first tumoral evaluation).

This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.

One tumour sampling.

Timing of blood sampling:

• before treatment
• at W8 of treatment (after radiological examination)
• at W12 of treatment
• at progression or 18 months after the beginning of treatment

This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.

One tumour sampling.

Timing of blood sampling:

• before treatment
• at W8 of treatment (after radiological examination)
• at W12 of treatment
• at progression or 18 months after the beginning of treatment

This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.

Timing of blood sampling:

• At inclusion
• After biopsy post inclusion (or in 15 days after)
• after 1 or 2 months of treatment
• at progression or 18 months after inclusion

This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.

Timing of blood sampling:

• At inclusion
• After biopsy post inclusion (or in 15 days after)
• after 1 or 2 months of treatment
• at progression or 18 months after inclusion

This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.

Timing of blood sampling :

• at inclusion
• at cycle 2 or 3 of treatment
• at the first tumoral evaluation (C5D1)
• at progression